Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Gong, Li Hua ^a   Chen, Xiu Xiu ^a   Wang, Huan ^b   Jiang, Qi Wei ^c   Pan, Shi Shi ^a   Qiu, Jian Ge ^c   Mei, Xiao Long ^c   Xue, You Qiu ^c   Qin, Wu Ming ^c   Zheng, Fei Yun ^a   Shi, Zhi ^c   Yan, Xiao Jian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; PLATINUM COMPOUNDS;

ANTICANCER PROPERTIES; CELL APOPTOSIS; COMBINATION THERAPY; G2/M PHASE ARRESTS; OVARIAN CANCER CELLS; OVARIAN CANCERS; REACTIVE OXIDATIVE SPECIES; THERAPEUTIC POTENTIALS;

CELL DEATH;

ANTINEOPLASTIC AGENT; CISPLATIN; PACLITAXEL; PIPERLONGUMINE EXTRACT; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; ACETYLCYSTEINE; PIPERLONGUMININE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; MEDICATION COMPLIANCE; OVARIAN CANCER CELL LINE; OVARY CANCER; OXIDATIVE STRESS; PIPER LONGUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; DRUG EFFECTS; FEMALE; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ACETYLCYSTEINE; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DIOXOLANES; DRUG SYNERGISM; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; OVARIAN NEOPLASMS; PACLITAXEL; REACTIVE OXYGEN SPECIES;

EID: 84901948210     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/906804     Document Type: Article

References (30)

1. Permuth-Wey J., Sellers T. A., Epidemiology of ovarian cancer. Methods in Molecular Biology 2009 472 413 437 2-s2.0-58149465743 10.1007/978-1-60327-492- 0-20
2. Cannistra S. A., Cancer of the ovary. The New England Journal of Medicine 2004 351 24 2519 2529 2-s2.0-19744368302 10.1056/NEJMra041842 (Pubitemid 39603165)
3. Chen L., Liang L., Yan X., Liu N., Gong L., Pan S., Lin F., Zhang Q., Zhao H., Zheng F., Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. International Journal of Gynecological Cancer 2013 23 2 256 263 10.1097/IGC.0b013e31827ad2b8
4. Yan X.-J., Liang L.-Z., Zeng Z.-Y., Shi Z., Fu L.-W., Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel. Ai Zheng 2006 25 4 398 403 2-s2.0-33846841194
5. Yan X.-J., Liang L.-Z., Zeng Z.-Y., Fu L.-W., Shi Z., Influence of short hairpin RNA on survivin mRNA expression and chemosensitivity to paclitaxel in ovarian cancer cells. Zhonghua Fu Chan Ke Za Zhi 2005 40 9 609 613 2-s2.0-33947155088
6. Yan X. J., Gong L. H., Zheng F. Y., Cheng K. J., Chen Z. S., Shi Z., Triterpenoids as reversal agents for anticancer drug resistance treatment. Drug Discovery Today 2013 10.1016/j.drudis.2013.07.018
7. Bose C. K., Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2008 17 5 231 238 2-s2.0-57749197372 10.3727/096504008786111383
8. Szatrowski T. P., Nathan C. F., Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Research 1991 51 3 794 798 2-s2.0-0026021362
9. Schumacker P. T., Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006 10 3 175 176 2-s2.0-33748165596 10.1016/j.ccr.2006.08.015 (Pubitemid 44311072)
10. Fang J., Seki T., Maeda H., Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Advanced Drug Delivery Reviews 2009 61 4 290 302 2-s2.0-64149087422 10.1016/j.addr.2009.02.005
11. Xue Y. Q., Di J. M., luo Y., Cheng K. J., Wei X., Shi Z., Resveratrol oligomers for the prevention and treatment of cancers. Oxidative Medicine and Cellular Longevity 2014 2014 9 765832 10.1155/2014/765832
12. Bezerra D. P., Pessoa C., de Moraes M. O., Saker-Neto N., Silveira E. R., Costa-Lotufo L. V., Overview of the therapeutic potential of piplartine (piperlongumine). European Journal of Pharmaceutical Sciences 2013 48 3 453 463 10.1016/j.ejps.2012.12.003
13. Bezerra D. P., Militão G. C. G., de Castro F. O., Pessoa C., de Moraes M. O., Silveira E. R., Lima M. A. S., Elmiro F. J. M., Costa-Lotufo L. V., Piplartine induces inhibition of leukemia cell proliferation triggering both apoptosis and necrosis pathways. Toxicology in Vitro 2007 21 1 1 8 2-s2.0-33845211116 10.1016/j.tiv.2006.07.007 (Pubitemid 44855506)
14. Bezerra D. P., Pessoa C., de Moraes M. O., Silveira E. R., Lima M. A. S., Elmiro F. J. M., Costa-Lotufo L. V., Antiproliferative effects of two amides, piperine and piplartine, from Piper species. Zeitschrift fur Naturforschung C: Journal of Biosciences 2005 60 7-8 539 543 2-s2.0-24344452031 (Pubitemid 41247248)
15. Liu J. M., Pan F., Li L., Liu Q. R., Chen Y., Xiong X. X., Cheng K., Yu S. B., Shi Z., Yu A. C., Chen X. Q., Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochemical and Biophysical Research Communications 2013 437 1 87 93 10.1016/j.bbrc.2013.06.042
16. Kong E.-H., Kim Y.-J., Kim Y.-J., Cho H.-J., Yu S.-N., Kim K.-Y., Chang J.-H., Ahn S.-C., Piplartine induces caspase-mediated apoptosis in PC-3 human prostate cancer cells. Oncology Reports 2008 20 4 785 792 2-s2.0-54949096135 10.3892/or-00000075
17. Bezerra D. P., De Castro F. O., Alves A. P. N. N., Pessoa C., De Moraes M. O., Silveira E. R., Lima M. A. S., Elmiro F. J. M., De Alencar N. M. N., Mesquita R. O., Lima M. W., Costa-Lotufo L. V., In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine. Journal of Applied Toxicology 2008 28 2 156 163 2-s2.0-41149150829 10.1002/jat.1261 (Pubitemid 351428288)
18. Raj L., Ide T., Gurkar A. U., Foley M., Schenone M., Li X., Tolliday N. J., Golub T. R., Carr S. A., Shamji A. F., Stern A. M., Mandinova A., Schreiber S. L., Lee S. W., Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011 475 7355 231 234 2-s2.0-79960427057 10.1038/nature10167
19. Adams D. J., Dai M. J., Pellegrino G., Wagner B. K., Stern A. M., Shamji A. F., Schreiber S. L., Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proceedings of the National Academy of Sciences of the United States of America 2012 109 38 15115 15120 10.1073/pnas.1212802109
20. Bezerra D. P., Moura D. J., Rosa R. M., de Vasconcellos M. C., e Silva A. C. R., de Moraes M. O., Silveira E. R., Lima M. A. S., Henriques J. A. P., Costa-Lotufo L. V., Saffi J., Evaluation of the genotoxicity of piplartine, an alkamide of Piper tuberculatum, in yeast and mammalian V79 cells. Mutation Research-Genetic Toxicology and Environmental Mutagenesis 2008 652 2 164 174 2-s2.0-42749089537 10.1016/j.mrgentox.2008.02.001
21. Makhov P., Golovine K., Teper E., Kutikov A., Mehrazin R., Corcoran A., Tulin A., Uzzo R. G., Kolenko V. M., Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. British Journal of Cancer 2014 110 899 907 10.1038/bjc.2013.810
22. Wang Y., Wang J. W., Xiao X., Shan Y., Xue B., Jiang G., He Q., Chen J., Xu H. G., Zhao R. X., Werle K. D., Cui R., Liang J., Li Y. L., Xu Z. X., Piperlongumine induces autophagy by targeting p38 signaling. Cell Death and Disease 2013 4 e824 10.1038/cddis.2013.358
23. Shi Z., Liang Y.-J., Chen Z.-S., Wang X.-W., Wang X.-H., Ding Y., Chen L.-M., Yang X.-P., Fu L.-W., Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biology & Therapy 2006 5 1 39 47 2-s2.0-32544451627 (Pubitemid 43234976)
24. Weil C. S., Tables for convenient calculation of median-effective dose (LD50 or ED50) and instructions in their use. Biometrics 1952 8 1 249 263 10.2307/3001557
25. Fang J., Nakamura H., Iyer A. K., Tumor-targeted induction of oxystress for cancer therapy. Journal of Drug Targeting 2007 15 7-8 475 486 2-s2.0-34547670578 10.1080/10611860701498286 (Pubitemid 47213870)
26. Silasi D.-A., Alvero A. B., Rutherford T. J., Brown D., Mor G., Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opinion on Pharmacotherapy 2009 10 6 1059 1067 2-s2.0-67649619170 10.1517/14656560902837980
27. Ott M., Gogvadze V., Orrenius S., Zhivotovsky B., Mitochondria, oxidative stress and cell death. Apoptosis 2007 12 5 913 922 2-s2.0-34247490186 10.1007/s10495-007-0756-2 (Pubitemid 46653300)
28. Fruehauf J. P., Meyskens F. L. Jr., Reactive oxygen species: a breath of life or death? Clinical Cancer Research 2007 13 3 789 794 2-s2.0-33847349283 10.1158/1078-0432.CCR-06-2082 (Pubitemid 46340350)
29. Okuno S., Sato H., Kuriyama-Matsumura K., Tamba M., Wang H., Sohda S., Hamada H., Yoshikawa H., Kondo T., Bannai S., Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. British Journal of Cancer 2003 88 6 951 956 2-s2.0-0242499988 10.1038/sj.bjc.6600786 (Pubitemid 36520886)
30. Maiti A. K., Gene network analysis of oxidative stress-mediated drug sensitivity in resistant ovarian carcinoma cells. The Pharmacogenomics Journal 2010 10 2 94 104 2-s2.0-77950023644 10.1038/tpj.2009.49